BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-03-04 00:46 |
Eisai påbörjar inlämning av lecanemab-data i Japan för förhandsgranskning, med …
|
Swedish | 193.3 KB | ||
| 2022-02-03 08:00 | Swedish | 1.1 MB | |||
| 2022-02-03 08:00 | English | 1.1 MB | |||
| 2021-12-24 01:35 |
Lecanemab beviljas Fast Track designation av amerikanska läkemedelsmyndigheten
|
Swedish | 227.5 KB | ||
| 2021-12-24 01:35 |
Lecanemab granted Fast Track designation by the FDA
|
English | 227.3 KB | ||
| 2021-11-01 08:30 |
BioArctic presents Nomination Committee
|
English | 213.1 KB | ||
| 2021-11-01 08:30 |
BioArctic presenterar valberedningen
|
Swedish | 212.6 KB | ||
| 2021-10-21 08:01 | English | 1.3 MB | |||
| 2021-10-21 08:00 | Swedish | 1.3 MB | |||
| 2021-09-28 01:38 |
Eisai påbörjar stegvis inlämning av ansökan till FDA för lecanemab vid tidig Al…
|
Swedish | 252.6 KB | ||
| 2021-09-28 01:38 |
Eisai initiates rolling submission for the US FDA Biologics license application…
|
English | 232.9 KB | ||
| 2021-07-09 08:01 | English | 9.8 MB | |||
| 2021-07-09 08:00 | Swedish | 10.1 MB | |||
| 2021-06-23 22:12 |
FDA beviljar Breakthrough Therapy designation för lecanemab i Alzheimers sjukdom
|
Swedish | 193.9 KB | ||
| 2021-06-23 22:12 |
FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer’s disease
|
English | 190.9 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
